

IN THE CLAIMS:

1. (Cancelled)
2. (Cancelled)
3. (Previously presented) The siRNA molecule of claim 37, wherein said siRNA molecule comprises one or more ribonucleotides.
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Previously presented) The siRNA molecule of claim 37, wherein the first strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the first strand.
17. (Original) The siRNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
18. (Cancelled)

19. (Cancelled)
20. (Cancelled)
21. (Previously presented) The siRNA molecule of claim 37, wherein said siRNA comprises one or more phosphorothioate internucleotide linkages.
22. (Cancelled)
23. (Previously presented) The siRNA molecule of claim 37, wherein each of the two strands of said siRNA molecule comprise 21 nucleotides.
24. (Previously presented) The siRNA molecule of claim 23, wherein about 19 nucleotides of each strand of the siRNA molecule are base-paired to the complementary nucleotides of the other strand of the siRNA molecule and wherein at least two 3' terminal nucleotides of each strand of the siRNA molecule are not base-paired to the nucleotides of the other strand of the siRNA molecule.
25. (Cancelled)
26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Previously presented) The siRNA molecule of claim 37, wherein the 5'-end of said second strand includes a phosphate group.
31. (Cancelled)
32. (Cancelled)
33. (Previously presented) A pharmaceutical composition comprising the siRNA molecule of claim 37 in an acceptable carrier or diluent.
34. (Cancelled)

35. (Cancelled)
36. (Cancelled)
37. (Currently Amended) A chemically synthesized double stranded short interfering RNA (siRNA) molecule consisting essentially of a first nucleic acid strand and a second nucleic acid strand, wherein
- [[a.]] (a) the first strand has complementarity to the second strand;
- [[b.]] (b) the second strand has 18-24 nucleotides complementary to a human synuclein-1 (SNCA) RNA comprising SEQ ID NO:311; and
- [[c.]] (c) one or more pyrimidine nucleotides present in the first strand or second strand of the siRNA molecule is a 2'-deoxy-2'-fluoro pyrimidine nucleotide and each purine nucleotide present in the first strand or second strand, or both the first strand and second strand of the siRNA molecule, is a 2'-O-methyl or 2'-deoxy purine nucleotide.
38. (Cancelled)
39. (Cancelled)
40. (Cancelled)